The Potential Impact of Maintaining a 3-Hour IV Thrombolysis Window: How Many More Patients can we Safely Treat?

Owners :

JsciMed

Created:

2014-01-30

The Potential Impact of Maintaining a 3-Hour IV Thrombolysis Window: How Many More Patients can we Safely Treat? BACKGROUND: In 2008, the European Cooperative Acute Stroke Study-3 (ECASS-3) demonstrated that intravenous-tissue plasminogen activator could be safely administered for acute stroke patients presenting between 3 and 4.5 hours from symptom onset. Recently, the Food and Drug Administration rejected expansion of this time window in the United States. We sought to determine how many fewer patients would be treated by maintaining this restricted time window. METHODS: We reviewed charts from patients who received intravenous thrombolysis at the University of Alabama at Birmingham between January 2009 and December 2011. Patients were divided into two groups (treated within 3 hours of onset, treated between 3 and 4.5 hours from onset). Demographics, stroke severity and protocol deviations according to the ECASS-3 trial were collected. Our safety measures were any hemorrhagic transformation, symptomatic intracerebral hemorrhage and systemic hemorrhage.

Open Access University of Minho - Portugal

Owners :

josekarvalho

Created:

2012-10-11

News about Open Access in Portugal and in the world (in portuguese)

My Blog

Owners :

JorgeHagenberg

Created:

2020-06-17

Machine Learning Blog

Owners :

JorgeHagenberg

Created:

2020-06-17

Intlinks

Owners :

JorgeHagenberg

Created:

2020-09-10